zorevunersen Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for zorevunersen comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Epilepsies, Myoclonic. Most recent publication: Zorevunersen in Children and Adolescents with Dravet Syndrome., N Engl J Med, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Zorevunersen in Children and Adolescents with Dravet Syndrome.
    Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026
    PubMed: PMID 41780062 · NCT04740476 · Epilepsies, Myoclonic

Publications by year

2026–2026: 1 publications.

2026
1

Publications by indication

Epilepsies, Myoclonic (1)

Publications by journal

  • N Engl J Med1 paper

All zorevunersen publications (1)

2026 (1 paper)

  1. Zorevunersen in Children and Adolescents with Dravet Syndrome.
    Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41780062 · NCT04740476 · Epilepsies, Myoclonic

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 26 May 2026 18:22:19 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).